Batra, Richa
Uni, Rie
Akchurin, Oleh M.
Alvarez-Mulett, Sergio
Gómez-Escobar, Luis G.
Patino, Edwin
Hoffman, Katherine L.
Simmons, Will
Whalen, William
Chetnik, Kelsey
Buyukozkan, Mustafa
Benedetti, Elisa
Suhre, Karsten
Schenck, Edward
Cho, Soo Jung
Choi, Augustine M. K.
Schmidt, Frank
Choi, Mary E.
Krumsiek, Jan http://orcid.org/0000-0003-4734-3791
Funding for this research was provided by:
NIA (1U19AG063744, R01AG069901-01)
NHLBI (K23 HL151876)
NIH NIDDK (K08 DK114558)
Qatar Foundation
NIH (NIH T32 HL134629-Martinez)
Article History
Received: 29 September 2022
Accepted: 11 January 2023
First Online: 26 January 2023
Declarations
:
: The study was approved by the institutional review board at Weill Cornell Medicine (protocol number 22-03024534). Written informed consent was received before participation by all patients, except when the institutional review board approved a waiver of informed consent (e.g., for the use of discarded samples and de-identified patient data).
: Not applicable.
: A.M.K.C. is a cofounder and equity stockholder for Proterris, which develops therapeutic uses for carbon monoxide. A.M.K.C. has a use patent on CO. Additionally, A.M.K.C. has a patent in COPD. ES consults for Axle informatics regarding COVID vaccine clinical trials through NIAID. JK holds equity in Chymia LLC and IP in PsyProtix and is cofounder of iollo.